
Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) has provided an update. Apimeds Pharmaceuticals US, Inc. is a Delaware corporation involved in Apitox-related rights. On August 19, 2026, it entered an
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| APUS | Apimeds Pharmaceuticals US, Inc. | 1.60 | -21.20 | -92.98% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.60 | -92.98% |

Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) has provided an update. Apimeds Pharmaceuticals US, Inc. is a Delaware corporation involved in Apitox-related rights. On August 19, 2026, it entered an

An update from Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) is now available. On Oct. 4, 2026, MindWave Innovations Inc., a subsidiary of Apimeds Pharmaceuticals US, Inc., signed a two-year

Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) just unveiled an announcement. Apimeds Pharmaceuticals US, Inc. announced that on September 29, 2026, Interim Chief Financial Officer Erick Frim resigned effective immediately,

Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) just unveiled an announcement. On September 24, 2026, MindWave Innovations Inc., a subsidiary of Apimeds Pharmaceuticals US, Inc., entered a 12‑month strategic technology

Apimeds Pharmaceuticals US stock rallied after the company reached a deal with AQUAE to manage AQUAEChain.

Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) has shared an update. Apimeds Pharmaceuticals US, Inc. implemented a one-for-ten reverse stock split of its issued and outstanding common stock, effective July

Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) has provided an announcement. On September 10, 2026, Apimeds Pharmaceuticals US, Inc. and its affiliated parties executed a first amendment to their April

The latest announcement is out from Apimeds Pharmaceuticals US, Inc. ( ($APUS) ). On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement with Korea-based

Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) has provided an announcement. On August 5, 2026, Apimeds Pharmaceuticals US, Inc. appointed Dr. Christopher Kim as Chief Scientific Officer, effective immediately, to

09:53 EDT Apimeds Pharmaceuticals (APUS) US Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.